TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05735197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin which is (SGLT2 inhibitor) will be used as add on medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
Study: NCT05817786

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation of the brachial plexus nerve roots
Description: treated by chronic electrical stimulation of the brachial plexus nerve roots

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham stimulation
Description: treated by sham stimulation
Study: NCT06186284

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: nerve conduction study
Description: sensory and motor nerve conduction study of both median nerves and ulnar nerves

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ultrasonography wrists
Description: assess the cross-sectional area of the median nerves and the ulnar nerves

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Boston carpal tunnel questionnaire
Description: assess the severity of symptoms and the functional impact related to carpal tunnel syndrome

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: clinical provocative tests for carpal tunnel syndrome
Description: Tinel and Phalen's test to evaluate the presence of carpal tunnel syndrome
Study: NCT06415240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking
Description: Facilitated Tucking is a position to be adopted for pain relief in neonates.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: while gentle human touch is caressing on head for pain relief.
Study: NCT05334940

Intervention type: OTHER
Intervention: not applicable, observational study
Description: Patients do not receive intervention
Study: NCT06014801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dialysate fluid, Filtration replacement fluid
Description: Dose of continuous hemodialysis and/or hemofiltration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate fluid, Filtration replacement fluid
Description: Dose of continuous hemodialysis and/or hemofiltration
Study: NCT05815498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.222
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.815
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.815
Description: Sterile liquid for injection
Study: NCT05430438

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with low dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with low dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 137 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with standard dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dialysis with standard dialysate sodium concentration
Description: Patients will undergo 4 dialysis sessions with a dialysate sodium concentration of 140 mEq/L. The modification of dialysate sodium concentration will be monitored through alteration of sodium conductivity
Study: NCT06495099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Russian electrical stimulation
Description: Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Russian electrical stimulation
Description: Type of Medium frequency current with 2500 Hz frequency modulated at 50 Hz with 50% Duty cycle training protocol is (10 sec. on time - 50 sec. off time - 10 minutes total time)
Study: NCT04855890

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: The ablation procedure will be performed during deep sedation using midazolam, fentanyl and a continuous infusion of propofol. Vital parameters will be monitored. For catheter access three 8F sheaths will be inserted into the femoral veins. A multipolar diagnostic catheter will be placed in the coronary sinus. Single transseptal puncture and insertion of a 8.5 F transseptal sheath or 12F Cryo-Sheath (FlexCath AdvanceTM, Medtronic, Minneapolis, MN, USA) will be followed by PV angiographies. Before or shortly after transseptal puncture unfractionated heparin will be repeatedly administered to maintain an activated clotting time between 250 and 400s.
Study: NCT06551727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.~In terms of blood pressure control, medications such as dopamine, metaraminol, or midodrine are used to achieve a systolic blood pressure target range of 160-180 mmHg within 1 h of random assignment and to maintain this target for 7 days (or death, should this event occur earlier). BP measurements are routinely captured using automated devices fitted to the unaffected arm, following the protocol recommended by the standard guideline. The readings are taken at 15-minute intervals for the initial hour, hourly from the first to the sixth hour, every six hours from 6 to 24 hours, and then twice daily for 7 days (or death, if earlier). Subsequently, these data are uploaded into the research database.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: After stroke progression, all patients receive dual antiplatelet therapy (aspirin 100mg/day combined with clopidogrel 75mg/day) for the first 21 days, except in cases of cerebral hemorrhage. After this period, they continue to take aspirin 100mg/day orally for the long term.
Study: NCT04715581

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional optimization
Description: 1. Indication for oral nutritional supplementation: Patients at risk of malnutrition (MNA-SF 8-11) or with malnutrition (MNA-SF 0-7).~2. Protocol of nutritional optimization: Enteral nutritional powder (Ensure for patients without diabetes and Glucerna for patients with diabetes) twice a day. The target protein intake is 1.5-1.8 g/kg/d. Patients with iron deficient anemia (hemoglobin \<130 g/L for men and \<120 g/L for women) will be given oral iron therapy.~3. The duration of nutritional optimization: The day admitted to the hospital to the surgery to one day prior to the surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative exercise training
Description: 1. The respiratory training will be performed for at least 2-3 times per day. Respiratory training include thoracic breathing exercise and cough training.~2. Aerobic exercise will be performed for at least 1-2 times per day. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Every training should be last for 45 minutes to 1 hour. If the patient can not tolerate, the training time should be reduce to 30 minutes.~4. The duration of exercise training: The day admitted to the hospital to the surgery to one day prior to the surgery.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative exercise training
Description: 1. Muscle strength training in the bedside and walking in the ward.~2. Aerobic exercise includes jogging, walking or climbing stairs. Exercise intensity will be based on patients' tolerance. The goal of the training is to complete the training plan as far as possible.~3. Exercise training is performed under the supervision of physiotherpists durign hospital stay, and is reminded by regular telephone calls and phone messages after hospital discharge.
Study: NCT05146232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitoring
Description: electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monitoring
Description: electrocardiogram, noninvasive blood pressure, SpO2, rSO2 (Masimo oximeter), and neuromuscular monitoring (TOF-Watch SX; Organon, Dublin, Ireland) were performed on the patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First postoperative analgesia
Description: IV acetaminophen will be administered every 6 h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First postoperative analgesia
Description: IV acetaminophen will be administered every 6 h

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second postoperative analgesia
Description: 50 mg IV dexketoprofen every 8 h for the first 48 h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Second postoperative analgesia
Description: 50 mg IV dexketoprofen every 8 h for the first 48 h.
Study: NCT06338553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule or tablet once before the pre-TZIELD® MMTT and once before one of the post-TZIELD® MMTTs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide (Rybelsus®)
Description: 7 mg single dose of Rybelsus® by mouth once before one of the post-TZIELD® MMTTs
Study: NCT06540911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized physical back training program
Description: The study intervention is a 4-week personalized physical back training program. The study intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are selected through a clinical reasoning process, i.e., they are tailored and problem-oriented, based on the results of a clinical assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalized physical back training program
Description: The control intervention is a 4-week non-personalized physical back training program. The control intervention consists of six exercises selected from a predefined set by a physical therapist or medical doctor. These exercises are not selected through a clinical reasoning process, i.e., they are neither tailored nor problem-oriented nor based on the results of a clinical assessment.
Study: NCT05851547

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate SBRT with Focal Boost
Description: Prostate stereotactic body radiotherapy delivered to 27 Gy in 3 fractions on alternating days to uninvolved regions with up to 39 Gy in 3 fractions delivered to mpMRI-defined intraprostatic lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin Injection
Description: Six months of androgen deprivation therapy for intermediate-risk localized prostate cancer and 24 months for high-risk localized prostate cancer
Study: NCT05829044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillometer measurement of pupil size in response to different light stimuli

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light box exposure
Description: Using a light box to produce different wavelengths and intensities of light. Exposure to red light on Night 1 and blue/green light on Night 2 to determine circadian timing and suppression of hormone (melatonin)
Study: NCT06284122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: 5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 20 mg/day Day 1 to Day 21 from C2 to C12

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m2 Day 1 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m2 Day 1 from C1 to C6
Study: NCT05115890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients with HFpEF will undergo 8 weeks of exercise training.
Study: NCT05046158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transforming Powder Dressing
Description: Altrazeal transforming powder dressing is methacrylate-based powder dressing made from the same materials used in the production of contact lenses. Upon hydration, the powder transforms into a moist, non-occlusive barrier that covers and protects the wound from exogenous bacteria while helping manage exudate through vapor transpiration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care topical wound agents and dressings
Description: Standard wound dressings such as gauze or foams. Moisture regulating topical agents may also be used to prepare the wound bed.
Study: NCT05904912

Intervention type: DRUG
Group type: OTHER
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management
Description: Intravenous 0.5 mg/kg tramodol and 1 gr paracetamol will be administered to all patients 30 minutes before the end of the surgical procedure. In the postoperative period, patients will be administered iparacetamol iv 1 gr 3x1. Postoperative patient evaluation will be performed by another pain nurse who is unaware of the procedure. If the NRS score is ≥ 4, 0.5 mg kg-1 iv meperidine will be administered as a rescue analgesic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG-Bupivacaine
Description: The probe will be placed on the anterior inferior iliac crest in the transverse plane. Then, the pubic ramus will be visualized by rotating 45 degrees. The femoral artery, iliopubic process, and psoas muscle will be visualized. The needle will be punctured with the in-plane method to reach between the pubic ramus and the psoas tendon. After the block area is confirmed with 5 ml of saline, 30 ml of local anesthetic solution containing 0.25% bupivacaine will be injected.

Intervention type: DRUG
Group type: OTHER
Intervention: Local infiltration-Bupivacaine
Description: Local infiltration will be applied with 30 ml of a local anesthetic solution containing 0.25% bupivacaine by the surgical team
Study: NCT05409495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgical procedure (open flap debridement)
Description: All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed The IBD area in the control group was closed without applying any material. Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontal surgical procedure (OFD +autogenous Titanium-prepared platelet-rich fibrin (OFD+ T-PRF))
Description: All surgical procedures were performed by the second periodontist. 0.12% Chlorhexidine digluconate (CHX) rinse for intraoral antisepsis and a povidone iodine solution was used for extraoral antisepsis. After local anesthesia (2% lidocaine with epinephrine 1:100,000/ Astra, Westbrough, MA) was applied, the full thickness trapezoidal flap was raised large enough to provide adequate view of the defect area. Subgingival debridement and root planning were performed with the use of area-specific curets (Gracey curets, Hu-Friedy), and granulation tissue was removed (Figure 2a). The blood supply of the defect areas was taken into account. At the test site, IBDs were filled with T-PRF and T-PRF membranes were adapted over the defects both buccally and lingually, in addition to OFD (Figure 2b). Then mucoperiosteal flaps were repositioned with sutured with 4/0 monoprolene sutures.
Study: NCT05942339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.
Study: NCT05925816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video uses BA techniques for approximately 5 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video uses BA techniques for approximately 5 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Video uses BA techniques for approximately 5 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active game
Description: Game provides positive feedback in response to decisions made by participants

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active game
Description: Game provides positive feedback in response to decisions made by participants

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral game
Description: Game without feedback

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral game
Description: Game without feedback
Study: NCT06116461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants receive three reduced doses of 240 mg every four weeks
Study: NCT06284122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 Day 1 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m2 Day 1 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin
Description: 1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin
Description: 1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
Study: NCT05388435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL27969
Description: SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL27969
Description: SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
Study: NCT06284122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day Day 1 to Day 5 from C1 to C6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day Day 1 to Day 5 from C1 to C6
Study: NCT06121180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIV-Aflibercept
Description: Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells.
Study: NCT05520099

Intervention type: PROCEDURE
Intervention: Core Needle or Forceps Biopsy
Description: Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
Study: NCT06239831

Intervention type: DEVICE
Intervention: ExSpiron and ActivPAL Monitors
Description: ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
Study: NCT04655495

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAPs /balanced gluten free diet
Description: Dietary Supplement: Balanced low FODMAPs /gluten free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAPs /balanced gluten free diet
Description: Dietary Supplement: Balanced low FODMAPs /gluten free diet